The DOI matches its Crossref record; 285 of the 285 references it cites were found in a registry or an index.
Epidemiology of Prostate Cancer
Open accessAbstract
Prostate cancer is the second most frequent cancer diagnosis made in men and the fifth leading cause of death worldwide. Prostate cancer may be asymptomatic at the early stage and often has an indolent course that may require only active surveillance. Based on GLOBOCAN 2018 estimates, 1,276,106 new cases of prostate cancer were reported worldwide in 2018, with higher prevalence in the developed countries. Differences in the incidence rates worldwide reflect differences in the use of diagnostic testing. Prostate cancer incidence and mortality rates are strongly related to the age with the highest incidence being seen in elderly men (> 65 years of age). African-American men have the highest incidence rates and more aggressive type of prostate cancer compared to White men. There is no evidence yet on how to prevent prostate cancer; however, it is possible to lower the risk by limiting high-fat foods, increasing the intake of vegetables and fruits and performing more exercise. Screening is highly recommended at age 45 for men with familial history and African-American men. Up-to-date statistics on prostate cancer occurrence and outcomes along with a better understanding of the etiology and causative risk factors are essential for the primary prevention of this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Urisman, A., Molinaro, R. J., Fischer, N., Plummer, S. J., Casey, G., Klein, E. A., Malathi, K., Magi-Galluzzi, C., Tubbs, R. R., Ganem, D., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020025 · Cited by 577
RetractedSchlaberg, R., Choe, D. J., Brown, K. R., Thaker, H. M., & Singh, I. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906922106 · Cited by 275
RetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
(1994) · New England Journal of Medicine · doi:10.1056/nejm199404143301501 · Cited by 4,737
Screening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., Fossati, N., Gross, T., Henry, A. M., Joniau, S., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.003 · Cited by 3,227
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Cited by
Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches
Sekhoacha, M., Riet, K., Motloung, P., Gumenku, L., Adegoke, A., & Mashele, S. (2022) · Molecules · doi:10.3390/molecules27175730 · Cited by 904
Kombe Kombe, A. J., Li, B., Zahid, A., Mengist, H. M., Bounda, G.-A., Zhou, Y., & Jin, T. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2020.552028 · Cited by 646
Epidemiology and Prevention of Prostate Cancer
Gandaglia, G., Leni, R., Bray, F., Fleshner, N., Freedland, S. J., Kibel, A., Stattin, P., Van Poppel, H., & La Vecchia, C. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.09.006 · Cited by 611
Natural Products as Anticancer Agents: Current Status and Future Perspectives
Naeem, A., Hu, P., Yang, M., Zhang, J., Liu, Y., Zhu, W., & Zheng, Q. (2022) · Molecules · doi:10.3390/molecules27238367 · Cited by 607
Hypoxia signaling in human health and diseases: implications and prospects for therapeutics
Luo, Z., Tian, M., Yang, G., Tan, Q., Chen, Y., Li, G., Zhang, Q., Li, Y., Wan, P., & Wu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01080-1 · Cited by 499
Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening
Wei, J. T., Barocas, D., Carlsson, S., Coakley, F., Eggener, S., Etzioni, R., Fine, S. W., Han, M., Kim, S. K., Kirkby, E., et al. (2023) · Journal of Urology · doi:10.1097/ju.0000000000003491 · Cited by 391
Pantanowitz, L., Quiroga-Garza, G. M., Bien, L., Heled, R., Laifenfeld, D., Linhart, C., Sandbank, J., Albrecht Shach, A., Shalev, V., Vecsler, M., et al. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30159-x · Cited by 360
Naringenin: A potential flavonoid phytochemical for cancer therapy
Motallebi, M., Bhia, M., Rajani, H. F., Bhia, I., Tabarraei, H., Mohammadkhani, N., Pereira-Silva, M., Kasaii, M. S., Nouri-Majd, S., Mueller, A.-L., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120752 · Cited by 328
High-Intensity Focused Ultrasound: A Review of Mechanisms and Clinical Applications
Bachu, V. S., Kedda, J., Suk, I., Green, J. J., & Tyler, B. (2021) · Annals of Biomedical Engineering · doi:10.1007/s10439-021-02833-9 · Cited by 297
Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis
Guccini, I., Revandkar, A., D'Ambrosio, M., Colucci, M., Pasquini, E., Mosole, S., Troiani, M., Brina, D., Sheibani-Tezerji, R., Elia, A. R., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.012 · Cited by 185
Dang, K., Castello, G., Clarke, S. C., Li, Y., Balasubramani, A., Boudreau, A., Davison, L., Harris, K. E., Pham, D., Sankaran, P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002488 · Cited by 76
Hooijman, E. L., Chalashkan, Y., Ling, S. W., Kahyargil, F. F., Segbers, M., Bruchertseifer, F., Morgenstern, A., Seimbille, Y., Koolen, S. L. W., Brabander, T., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050715 · Cited by 59
Network approach in liquidomics landscape
Santini, D., Botticelli, A., Galvano, A., Iuliani, M., Incorvaia, L., Gristina, V., Taffon, C., Foderaro, S., Paccagnella, E., Simonetti, S., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02743-9 · Cited by 37
SLC4A4 promotes prostate cancer progression in vivo and in vitro via AKT-mediated signalling pathway
Liu, Z., Wang, Q., Zhai, G., Ke, S., Yu, X., & Guo, J. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02546-6 · Cited by 22
Iqbal, H., Inam‐Ur‐Raheem, M., Munir, S., Rabail, R., Kafeel, S., Shahid, A., Mousavi Khaneghah, A., & Aadil, R. M. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.3869 · Cited by 19
Fan, H., Li, J., Manuel, A. M., & Zhao, Z. (2023) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2023.02.022 · Cited by 14
Ye, Q., Zhou, X., Ren, H., Han, F., Lin, R., & Li, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1274336 · Cited by 15
Sousa, A., Coelho, P., Leite, F., Teixeira, C., Rocha, A. C., Santos, I., Baylina, P., Fernandes, R., Soares, R., Costa, R., et al. (2023) · Human Cell · doi:10.1007/s13577-023-00880-z · Cited by 15
Shen, Z., Pei, Q., Zhang, H., Yang, C., Cui, H., Li, B., Liu, J., Bo, Z., Wei, F., Zhang, M., et al. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001294 · Cited by 11
Metadata
- Authors
- Rawla, P.
- Venue
- World Journal of Oncology
- Publisher
- Elmer Press, Inc.
- Published
- 2019
- Volume
- 10
- Issue
- 2
- Pages
- 63-89
- ISSN
- 1920-4531 (ISSN-L)
- 1920-454X
- OpenAlex
- W2937483840
- Cited by
- 2,776
- References
- 285
- FWCI
- 195.03
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.